BROAD CLINICAL PROGRAM ONGOING SPONSOR PHASE INDICATION REGISTRATION PAXALISIB Global Coalition for Adaptive Research II / III Glioblastoma NCT03970447 Weill Medical College of Cornell II Glioblastoma (with metformin and ketogenesis) NCT05183204 Alliance for Clinical Trials in Oncology II Brain metastases NCT03994796 Dana-Farber Cancer Institute II Breast cancer brain metastases (with Herceptin) NCT03765983 Dana-Farber Cancer Institute II Primary CNS lymphoma NCT04906096 University of Sydney I/II Grade 2/3 IDH-mutant adult gliomas TBD Pacific Pediatric Neuro-Oncology Consortium II DIPG (childhood brain cancer) NCT05009992 Australia & New Zealand Children’s Oncology Group II Advanced solid tumours in children TBD St Jude Children’s Research Hospital I DIPG NCT03696355 Memorial Sloan Kettering Cancer Center I Brain metastases (with radiotherapy) NCT04192981 EVT801 Kazia Therapeutics I Advanced solid tumours NCT05114668 CLINICAL DEVELOPMENT OVERVIEW 11 Kazia Theraputics Limited Annual Report 2023 Paxalisib Investigational, small molecule, potent, brain-penetrant inhibitor of PI3K / mTOR licensed from: PRECLINICLE PHASE 1 PHASE 2 PHASE 3 MARKET Anticipated Glioblastoma & IDH-mutant glioma Common primary brain cancer Final Data 2H CY23 DIPG/Advanced Solid Tumors Childhood brain cancer Initial Data 3Q CY23 AT/RT Childhood brain cancer Further Data 1H CY23 Brain Metastases Cancer that spreads to brain from elsewhere Further Data CY23 Primary CNS Lymphoma Form of non-Hodgkin’s lymphoma Initial Data CY23 Cancers outside the CNS Melanoma; TNBC, Ovarian Further Data CY23 EVT801 Investigational, small molecule, highly specific inhibitor of VEGFR3 licensed from: Advanced Solid Tumors Patients w/ highly treatment-resistant cancer Initial Data 2H CY23 3 studies 3 studies 3 studies 3 studies IDH: Isocitrate dehydrogenase, DIPG: Diffuse Intrinsic Pontine Glioma, AT/RT: Atypical Teratoid Rhabdoid Tumor, CNS: central nervous system, TNBC: triple negative breast cancer, VEGFR3: vascular endothelial growth factor receptor 3. Chairman and CEO’s Letter Key Milestones Introduction to Kazia’s CEO Pipeline Review Environment, Society and Governance Financial Reports
RkJQdWJsaXNoZXIy MjE2NDg3